Michael Morris, MD

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study

annalsofoncology.org/article/S092...

Congratulations to MSK's Dr. Justin Jee and Dr. Nikolaus Schultz for being accepted into Round 2 of @statnews.com #STATMadness. Vote for the team “Cancer Big Data” now: www.statnews.com/feature/stat...

Congratulations to MSK's Dr. Natasha Rekhtman and Dr. Charles Rudin for being accepted into Round 1 of @statnews.com #STATMadness. Vote for the team “New Lung Cancer Subtype” now: www.statnews.com/feature/stat...

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.

Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore

www.appliedclinicaltrialsonline.com/view/fda-app...

Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP). #GU25
@charlesryanmd.bsky.social @mjmorrismd.bsky.social @ascopost.bsky.social meetings.asco.org/abstracts-pr...

So privileged to be among friends and colleagues for the second Feng symposium. Felix was friend and exemplar to us all.

Oncology Society Urges Americans to Heed Surgeon General Advisory on Alcohol and Cancer The U.S. Surgeon General’s office released a new advisory on the link between alcohol consumption and increased risk for cancer. The advisory reports alcohol use as the third leading preventable cause...

American Society of Clinical Oncology (ASCO) provides advisory support for the association between alcohol & cancer. @ascocancer.bsky.social @ascopost.bsky.social

society.asco.org/news-initiat...

AMBASSADOR Trial: Adjuvant pembrolizumab improved disease-free survival in high-risk muscle-invasive urothelial carcinoma post-surgery (29.6 vs 14.2 months; HR 0.73). Grade ≥3 AEs: 50.6%.
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social

The Prostate Cancer Clinical Trials Consortium (PCCTC) on LinkedIn: PCCTC Data Management Internship, Remote in | Careers at Remote The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data…

@thepcctc.bsky.social is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data Science, and Clinical Operations. For more info please visit www.linkedin.com/posts/prosta...

Nobody capture the holiday spirit more than @mskcancercenter.bsky.social facilities and engineering staff. Thanks for lifting our spirits with your decorations!

I just helped save a life You can save one, too. Donate now.

Heartbroken💔we lost Dr. Felix Feng— close friend, selfless collaborator, brilliant scientist. We miss you--too early my friend.

To all: please consider supporting this ACS/ASTRO award in Felix name:

donate.cancer.org/g/tjjfqwdnrxrl…?

Telehealth Will Die In 3 Weeks Without Congressional Action Urgent action is needed to pass the Telehealth Modernization Act before it expires, ending telemedicine on Dec. 31. This would be devastating for disabled and rural patients.

Telehealth Will Die In 3 Weeks Without Congressional Action www.forbes.com/sites/judyst...

A big thank you to the GU Oncologists and Nuc Meds of CTIC in Bogota, Colombia for their hospitality and scientific discussions. Great cancer center and #ProstateCancer care to be sure. Hope to work together in the future! Thanks to PCF for funding this scientific exchange.

Welcome, Toni - we are all the better for your arrival!

Agree - EMBARK doesn’t speak to this issue. The GOC of salvage RT is cure. The GOC of EMBARK is MFS. Different contexts and purposes; both have a role in helping pts with BCR #ProstateCancer.

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Abstract. Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine prostate cancer (NEPC) occurs in up to 15-20% of patients with castration-resistant prostate c...

Just in time for Thanksgiving, nice pathology framework for characterizing treatment emergent neuroendocrine #ProstateCancer, a biologically diverse entity that everyone has a hard time describing, in CCR - thanks to Michael Haffner and @mishabeltran.bsky.social
aacrjournals.org/clincancerre...

Nice point. Also, a negative trial isn’t a failed study if successfully completed and well designed with a clear readout. It’s just….negative.

Life could be a little bit hard for a junior scientist.

We share your pride!

Proud of my sister. Calm, deliberative, and forward focused. @blandro.bsky.social

youtube.com/watch?v=w2ft...

Outstanding article and beautifully written.

Thanks for doing this!

I remember my first-gen 128k Mac very fondly! Very musical drive noises...

Thanks for the reminder! Really looking forward to the meeting this year.

Interesting contrast to OS in STAMPEDE. Food for thought there.

I think you just said what the rest of us have been thinking all week.

Wish I could be there!

Physicians Flock to Bluesky, Hoping to Leave X Behind Many compare it to the early days of Twitter

Good write up of BlueSky #MedSky by @kristinafiore.bsky.social feat.
BlueSky elders:
@mdaware.org @gavinyamey.bsky.social @nickmark.bsky.social @kiswanson.bsky.social and @kidneyboy.bsky.social of course

www.medpagetoday.com/special-repo...

So great to see this published. This is such important work. Thank you to Silke and Aurelius for this indispensable #prostatecancer resource!

Agreed - a very interesting perspective and well worth reading and thinking about.